Which hedge funds own ROIV? ROIVANT SCIENCES LTD, Q2 2026 13F holders
Healthcare · Open on the interactive board
13 of the hedge funds tracked by WhaleCreep disclosed a position in ROIV (ROIVANT SCIENCES LTD) in their Q2 2026 13F filings, worth $1.7bn in total. The largest holder by portfolio weight is Farallon Capital Management at 3.0% of its book. 1 manager opened a new position this quarter: Polen Capital Management.
13tracked managers holding
1opened this quarter
0exited this quarter
Which hedge funds hold ROIV? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Farallon Capital Management | Q2 2026 | 3.0% | $506.4m | 14,309,000 | 48% | added |
| Rubric Capital Management | Q2 2026 | 1.9% | $212.3m | 6,000,000 | 20% | added |
| Maverick Capital | Q2 2026 | 0.9% | $100.1m | 2,829,024 | 74% | added |
| Viking Global Investors | Q2 2026 | 0.6% | $221.9m | 6,271,467 | -6% | reduced |
| Woodline Partners | Q2 2026 | 0.3% | $88.5m | 2,500,673 | 43% | added |
| Brevan Howard Capital Management | Q2 2026 | 0.3% | $18.3m | 517,621 | 344% | added |
| Point72 Asset Management LP | Q2 2026 | 0.2% | $158.3m | 4,473,478 | 402% | added |
| Citadel Advisors | Q2 2026 | 0.1% | $197.3m | 5,576,261 | 122% | added |
| D. E. Shaw & Co | Q2 2026 | 0.1% | $105.2m | 2,972,702 | 113% | added |
| Marshall Wace | Q2 2026 | 0.0% | $50.3m | 1,421,478 | -37% | reduced |
| Millennium Management | Q2 2026 | 0.0% | $24.8m | 700,494 | -13% | reduced |
| Polen Capital Management | Q2 2026 | 0.0% | $306.4k | 8,659 | – | new |
| First Manhattan | Q2 2026 | 0.0% | $394.5k | 11,146 | 0% | held |
How has hedge fund ownership of ROIV changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 13 | $1.7bn |
| Q1 2026 | 12 | $905.3m |
| Q4 2025 | 7 | $374.6m |
| Q3 2025 | 6 | $746.2m |
| Q2 2025 | 7 | $695.2m |
| Q1 2025 | 7 | $708.3m |
| Q4 2024 | 6 | $884.1m |
| Q3 2024 | 7 | $996.0m |
| Q2 2024 | 8 | $1.1bn |
| Q1 2024 | 8 | $1.1bn |
| Q4 2023 | 7 | $1.2bn |
| Q3 2023 | 8 | $1.2bn |
| Q2 2023 | 8 | $877.3m |
| Q1 2023 | 5 | $721.7m |
| Q4 2022 | 5 | $772.6m |
| Q3 2022 | 4 | $294.0m |
Counts every tracked manager that disclosed ROIV in that quarter's filing, including managers that have since stopped filing.